Skip to main content

The TODAY2 study

Update 06-09-2019 TODAY2 confirms steep type 2 diabetes trajectory in youth

Presenter: Kimberly Drews, PhD; Lorraine E. Levitt Katz, MD; Petter Bjornstad, MD; Neil H. White, MD; Jeanie B. Tryggestad, MD; Ruth S. Weinstock, MD, PhD.

Saturday 8 June: 13:45–15:45

The TODAY study found that metformin produced “durable” glycemic control in only approximately half of children aged 10–17 years given the medication to combat type 2 diabetes. The addition of rosiglitazone significantly improved glycemic outcomes, but intensive lifestyle intervention did not.

At ADA, the investigators will report the longer-term disease course in the TODAY participants who signed up for the observational follow-up study, TODAY2. Based on accumulating evidence, the team is anticipating rapid diabetes progression and the development of complications.

More on this trial